We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a ...

Feedback notes the proliferation of AI company logos, and agrees with one blogger's claim that many bear a striking ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

Amgen ( NASDAQ: AMGN) expects revenue of $34.3B-$35.7B and non-GAAP EPS of $20.00-$21.20 for full year 2025. A Seeking Alpha ...

Key growth drivers include major biologics' patent expirations and cost-effectiveness, while European market leads with 45.8% share in 2023.Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Biosimilars: ...

Amgen is preparing to release its Q1 2025 earnings, with analysts expecting $4.18 EPS and $8.05 billion in revenue. In its ...

Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...

Hancock Whitney Corp shaved off 5.6% of its Amgen holdings during the fourth quarter, selling 2,474 shares but still ...

Amgen will invest $900M to expand its Columbus region biomanufacturing facility, bringing total investment in Central Ohio to ...

THOUSAND OAKS, Calif., April 25, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $900 million expansion of its ...

Learn how a 25% Pharma tariff could raise U.S. drug costs by nearly $51 billion annually and impact prices significantly.

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement ...